{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:26:57Z","timestamp":1765546017403},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Europace"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1093\/europace\/euv068","type":"journal-article","created":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T16:53:09Z","timestamp":1435337589000},"page":"1007-1017","source":"Crossref","is-referenced-by-count":48,"title":["Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation"],"prefix":"10.1093","volume":"17","author":[{"given":"A. John","family":"Camm","sequence":"first","affiliation":[]},{"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Graeme J.","family":"Hankey","sequence":"additional","affiliation":[]},{"given":"Felicita","family":"Andreotti","sequence":"additional","affiliation":[]},{"given":"F.D. Richard","family":"Hobbs","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2015,6,26]]},"reference":[{"key":"2015062609244668000_17.7.1007.1","unstructured":"World Health Organization. The top 10 causes of death (Fact sheet no 310). 2014. http:\/\/www.who.int\/mediacentre\/factsheets\/fs310\/en\/index.html (6 January 2015, date last accessed)."},{"key":"2015062609244668000_17.7.1007.2","unstructured":"World Heart Federation. The global burden of stroke. 2014. http:\/\/www.world-heart-federation.org\/cardiovascular-health\/stroke\/ (6 January 2015, date last accessed)."},{"key":"2015062609244668000_17.7.1007.3","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"key":"2015062609244668000_17.7.1007.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2007.09.002"},{"key":"2015062609244668000_17.7.1007.5","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eur132"},{"key":"2015062609244668000_17.7.1007.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192667"},{"key":"2015062609244668000_17.7.1007.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.05.042"},{"key":"2015062609244668000_17.7.1007.8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2888"},{"key":"2015062609244668000_17.7.1007.9","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.27.10.1765"},{"key":"2015062609244668000_17.7.1007.10","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.27.10.1760"},{"key":"2015062609244668000_17.7.1007.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00160.x"},{"key":"2015062609244668000_17.7.1007.12","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eus305"},{"key":"2015062609244668000_17.7.1007.13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063479"},{"key":"2015062609244668000_17.7.1007.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2015062609244668000_17.7.1007.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"2015062609244668000_17.7.1007.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"2015062609244668000_17.7.1007.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"2015062609244668000_17.7.1007.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2011.02257.x"},{"key":"2015062609244668000_17.7.1007.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70042-X"},{"key":"2015062609244668000_17.7.1007.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70274-X"},{"key":"2015062609244668000_17.7.1007.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70092-3"},{"key":"2015062609244668000_17.7.1007.22","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0b013e3181f7d043"},{"key":"2015062609244668000_17.7.1007.23","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2304"},{"key":"2015062609244668000_17.7.1007.24","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eul097"},{"key":"2015062609244668000_17.7.1007.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.022"},{"key":"2015062609244668000_17.7.1007.26","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut083"},{"key":"2015062609244668000_17.7.1007.27","unstructured":"National Institute for Health and Care Excellence. Clinical guideline 180: the management of atrial fibrillation. 2014. http:\/\/www.nice.org.uk\/guidance\/CG180 (6 January 2015, date last accessed)."},{"key":"2015062609244668000_17.7.1007.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2012.01.021"},{"key":"2015062609244668000_17.7.1007.29","doi-asserted-by":"crossref","unstructured":"Ogawa S Aonuma K Tse HF Huang D Huang JL Kalman J The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J Arrhythmia 2014;29:190\u2013200.","DOI":"10.1016\/j.joa.2013.03.002"},{"key":"2015062609244668000_17.7.1007.30","doi-asserted-by":"crossref","unstructured":"Cappato R Ezekowitz MD Klein AL Camm AJ Ma CS Le Heuzey JY Rivaroxaban versus vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; doi:10.1093\/eurheartj\/ehu367 .","DOI":"10.1093\/eurheartj\/ehu367"},{"key":"2015062609244668000_17.7.1007.31","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euq080"},{"key":"2015062609244668000_17.7.1007.32","doi-asserted-by":"crossref","unstructured":"Lip GYH Noack H Ferreira J Connolly SJ Yusuf S . Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014;111:933\u201342.","DOI":"10.1160\/TH13-09-0734"},{"key":"2015062609244668000_17.7.1007.33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005451"},{"key":"2015062609244668000_17.7.1007.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.12.006"},{"key":"2015062609244668000_17.7.1007.35","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi505"},{"key":"2015062609244668000_17.7.1007.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-008-3177-2"},{"key":"2015062609244668000_17.7.1007.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-011-0320-5"},{"key":"2015062609244668000_17.7.1007.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.03.053"},{"key":"2015062609244668000_17.7.1007.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.11.026"},{"key":"2015062609244668000_17.7.1007.40","doi-asserted-by":"crossref","unstructured":"Olesen JB, S\u00f8rensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant na\u00efve atrial fibrillation patients: Danish nationwide descriptive data 2011\u20132013. Europace 2015;17:187\u201393.","DOI":"10.1093\/europace\/euu225"},{"key":"2015062609244668000_17.7.1007.41","doi-asserted-by":"crossref","unstructured":"Lip GY, Bongiorni MG, Dobreanu D, Lewalter T, Hastrup Svendsen J, Blomstr\u00f6m-Lundqvist C et al. Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey. Europace 2013;15:1526\u201332.","DOI":"10.1093\/europace\/eut292"},{"key":"2015062609244668000_17.7.1007.42","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut263"},{"key":"2015062609244668000_17.7.1007.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.11.015"},{"key":"2015062609244668000_17.7.1007.44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.113.000127"},{"key":"2015062609244668000_17.7.1007.45","doi-asserted-by":"publisher","DOI":"10.1136\/ha.2010.002691"},{"key":"2015062609244668000_17.7.1007.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.07.002"},{"key":"2015062609244668000_17.7.1007.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901301"},{"key":"2015062609244668000_17.7.1007.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007432"},{"key":"2015062609244668000_17.7.1007.49","doi-asserted-by":"publisher","DOI":"10.1159\/000091546"},{"key":"2015062609244668000_17.7.1007.50","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-12-98"},{"key":"2015062609244668000_17.7.1007.51","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-88-0001"},{"key":"2015062609244668000_17.7.1007.52","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-12-0454"},{"key":"2015062609244668000_17.7.1007.53","unstructured":"Scottish Medicines Consortium. Rivaroxaban 15 and 20 mg film-coated tablets (Xarelto\u00ae) SMC No. (756\/12). 2012. http:\/\/www.scottishmedicines.org.uk\/files\/advice\/rivaroxaban_Xarelto_for_AF_FINAL_Jan_2012_for_website.pdf (6 January 2015, date last accessed)."},{"key":"2015062609244668000_17.7.1007.54","unstructured":"Northamptonshire Prescribing Advisory Group. Implementation of NICE TAs 249, 256 and 275. 2013. http:\/\/www.neneccg.nhs.uk\/resources\/uploads\/files\/implementation-of-nice-tas-249-256-and-275-dabigatran-rivaroxaban-and-apixaban-april-2013-final.pdf (6 January 2015, date last accessed)."},{"key":"2015062609244668000_17.7.1007.55","unstructured":"NHS Dorset Clinical Commissioning Group. Position statement on oral anticoagulants in atrial fibrillation. 2014. http:\/\/www.dorsetccg.nhs.uk\/Downloads\/aboutus\/medicines-management\/Other%20Guidelines\/NOACs%20in%20AF.pdf (December 2014, date last accessed)."},{"key":"2015062609244668000_17.7.1007.56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-4949.2012.00845.x"},{"key":"2015062609244668000_17.7.1007.57","doi-asserted-by":"publisher","DOI":"10.1159\/000131083"},{"key":"2015062609244668000_17.7.1007.58","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Criterios y recomendaciones generales para el uso de nuevos anticoagulantes orales en la prevenci\u00f3n del ictus y la embolia sist\u00e9mica en pacientes con FA no valvular. Informe de utilidad terap\u00e9utica 24 de septiembre de 2012. 2012. http:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/criterios-anticoagulantes-orales.pdf (8 January 2015, date last accessed)."},{"key":"2015062609244668000_17.7.1007.59","doi-asserted-by":"crossref","unstructured":"Biskupiak J Ghate SR Jiao T Brixner D . Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation. J Manag Care Pharm 2013;19:789\u201398.","DOI":"10.18553\/jmcp.2013.19.9.789"},{"key":"2015062609244668000_17.7.1007.60","unstructured":"National Institute for Health and Clinical Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. Technology appraisal 261. 2012. http:\/\/www.nice.org.uk\/ta261 (26 January 2015, date last accessed)."},{"key":"2015062609244668000_17.7.1007.61","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0087-9"},{"key":"2015062609244668000_17.7.1007.62","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-013-0144-3"},{"key":"2015062609244668000_17.7.1007.63","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.1999.640449.x"},{"key":"2015062609244668000_17.7.1007.64","doi-asserted-by":"crossref","unstructured":"Ghate SR Biskupiak J Ye X Kwong WJ Brixner DI . All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm 2011;17:672\u201384.","DOI":"10.18553\/jmcp.2011.17.9.672"},{"key":"2015062609244668000_17.7.1007.65","unstructured":"National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. Technology appraisal TA256. 2012. http:\/\/www.nice.org.uk\/ta256 (6 January 2015, date last accessed)."},{"key":"2015062609244668000_17.7.1007.66","unstructured":"National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. Technology appraisal TA249. 2012. http:\/\/www.nice.org.uk\/ta249 (6 January 2015, date last accessed)."},{"key":"2015062609244668000_17.7.1007.67","unstructured":"National Institute for Health and Care Excellence. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. Technology appraisal TA275. 2013. http:\/\/www.nice.org.uk\/guidance\/TA275 (6 January 2015, date last accessed)."},{"key":"2015062609244668000_17.7.1007.68","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.000402"},{"key":"2015062609244668000_17.7.1007.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.05.011"},{"key":"2015062609244668000_17.7.1007.70","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2011-300646"},{"key":"2015062609244668000_17.7.1007.71","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-1-201101040-00289"},{"key":"2015062609244668000_17.7.1007.72","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.985655"},{"key":"2015062609244668000_17.7.1007.73","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-02-0089"},{"key":"2015062609244668000_17.7.1007.74","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0b013e318247bcb6"},{"key":"2015062609244668000_17.7.1007.75","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03989.x"},{"key":"2015062609244668000_17.7.1007.76","unstructured":"Royal College of Physicians. Stroke improvement national audit programme (SINAP). 2012. http:\/\/www.rcplondon.ac.uk\/sites\/default\/files\/sinap-comprehensive-public-report-2012.pdf (6 January 2015, date last accessed)."},{"key":"2015062609244668000_17.7.1007.77","unstructured":"Canadian Stroke Network. The quality of stroke care in Canada. 2011. http:\/\/www.strokebestpractices.ca\/wp-content\/uploads\/2011\/06\/QoSC-EN.pdf (6 January 2015, date last accessed)."},{"key":"2015062609244668000_17.7.1007.78","doi-asserted-by":"publisher","DOI":"10.5694\/mja12.11779"},{"key":"2015062609244668000_17.7.1007.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.03.016"},{"key":"2015062609244668000_17.7.1007.80","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.783688"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/europace\/article-pdf\/17\/7\/1007\/7113518\/euv068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T12:11:25Z","timestamp":1503576685000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article-lookup\/doi\/10.1093\/europace\/euv068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,26]]},"references-count":80,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,6,26]]},"published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1093\/europace\/euv068"],"URL":"https:\/\/doi.org\/10.1093\/europace\/euv068","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,26]]}}}